Related Experiment Video
Updated: Jan 13, 2026
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Modified mRNA-Based Therapeutic Strategies for Myocardial Ischemia-Reperfusion Injury
1School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai 200093, China.
Insights
Modified RNA (modRNA) technology offers a promising new approach to treating myocardial ischemia-reperfusion injury (MIRI) by enabling targeted gene delivery. This innovative strategy shows potential for mitigating cardiac damage after reperfusion therapies for ischemic heart disease.
Area of Science:
- Cardiovascular Research
- Molecular Medicine
- Biotechnology
Background:
- Ischemic heart disease (IHD) is a leading global cause of mortality.
- Reperfusion therapies like PCI and CABG can paradoxically cause myocardial ischemia-reperfusion injury (MIRI).
- MIRI pathogenesis involves complex mechanisms including oxidative stress, inflammation, and apoptosis.
Purpose of the Study:
- To review recent advances in modified RNA (modRNA) delivery systems for MIRI treatment.
- To explore the potential of modRNA technology in mitigating reperfusion-related cardiac injury.
- To highlight challenges and future directions for clinical translation of modRNA-based therapies.
Main Methods:
- Review of current literature on modRNA technology and MIRI.
- Analysis of modRNA delivery systems for targeted gene expression (e.g., antioxidant, anti-apoptotic factors).
- Discussion of molecular mechanisms underlying MIRI and modRNA therapeutic applications.
Main Results:
- modRNA technology demonstrates enhanced stability, reduced immunogenicity, and controllable protein expression for therapeutic applications.
- Optimized modRNA delivery systems facilitate localized gene expression at injury sites, mitigating MIRI.
- Therapeutic genes delivered via modRNA can reduce oxidative stress, inflammation, and apoptosis in MIRI models.
Conclusions:
- modRNA-based delivery systems represent a novel and promising therapeutic strategy for MIRI.
- Further research is needed to overcome challenges in delivery system targeting, transfection efficiency, and cytotoxicity for clinical translation.
- Understanding MIRI mechanisms and modRNA characteristics can drive development of effective reperfusion injury treatments.
Abstract:
Ischemic heart disease (IHD), the leading causes of cardiovascular morbidity and mortality worldwide, is currently treated though revascularization strategies such as pharmacological thrombolysis, coronary artery bypass grafting (CABG), and percutaneous coronary intervention (PCI). However, the restoration of blood flow often induces cardiac dysfunction, known as myocardial ischemia-reperfusion injury (MIRI). The pathogenesis of MIRI involves a complex, multifactorial process characterized by the interplay of diverse pathophysiological mechanisms, including oxidative stress, intracellular calcium overload, inflammatory cascade activation, apoptosis, autophagy, and microvascular endothelial dysfunction. In recent years, modified RNA (modRNA) technology has emerged as a novel therapeutic strategy for MIRI due to its enhanced molecular stability, reduced immunogenicity, and controllable transient protein expression. Studies have demonstrated that optimized modRNA delivery systems enable efficient, localized expression of therapeutic genes (e.g., antioxidant, anti-apoptotic, and pro-angiogenic factors) at injury sites, significantly mitigating MIRI-associated pathological damage. Nevertheless, significant challenges remain in clinical translation, such as delivery system targeting, transfection efficiency and cytotoxicity. This review focuses on recent advances in the development and application of modRNA-based delivery systems for MIRI treatment. Understanding the molecular mechanisms of MIRI and the structural characteristics and application of modRNA may encourage researchers to explore promising therapeutic modalities for addressing reperfusion-related cardiac injury.
